Innovation to commercialization


Published on

December 8th 2010: The 6th annual Dutch Life Sciences and Health conference was held in de Beurs van Berlage, Amsterdam. Willem de Laat, Managing Director at Life Sciences Health, talks about 'Innovation to commercialization'.

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

No Downloads
Total Views
On Slideshare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide
  • EIM Report: Het cluster drugs bestaat uit bedrijven waarvoor geneesmiddelen en vaccins de belangrijkste afzetmarkten vormen. Ongeveer 44% van alle bedrijven (circa 430) maakt hier deel van uit. Zij tekenen voor een gezamenlijke om-zet van € 12 miljard en herbergen circa 37.000 werknemers, waarvan er 6.300 werkzaam zijn op R&D-gebied. In dit cluster zitten vanzelfsprekend ook veel farmaceutische bedrijven Het cluster diagnostics bevat bedrijven waarvoor diagnostische stoffen, bio-informatica, imaging en andere diagnostische apparatuur de belangrijkste deelmarkten zijn. Ongeveer 40% van de bedrijven (circa 390) maakt hier deel van uit. Zij zijn goed voor een totale omzet van € 2,7 miljard en voor een totale werkgelegenheid van ruim 12.000, waaronder bijna 2.000 R&D-werknemers. Het cluster biomedical engineerig & devices herbergt bedrijven waarvoor cel-enigineering, biomaterialen en kunstorganen belangrijke afzetmarkten vormen. Ongeveer 75 bedrijven maken hier deel van uit (7,6% van het to-taal); het cluster is goed voor een omzet van € 560 miljoen. In dit cluster zijn 3.400 personen, waarvan de helft op R&D-gebied. Cluster divers omvat bedrijven die binnen de Life Sciences & Gezondheid sector werkzaam zijn en waarvoor overige medische instrumenten de be-langrijkste afzetmarkt vormen. Ruim 40 bedrijven maken hier deel van uit. Omzet: € 400 miljoen. Dit cluster herbergt 2.200 werkzame personen waar-van ongeveer 10% wordt ingezet op R&D-gebied. drijven, waaronder enkele grote.
  • That was the past…Today the life sciences sector is not just blooming in Amsterdam, but in the whole of the Netherlands. In 2009 the Netherlands features a highly innovative, world leading, concentrated and growing cluster of life sciences companies academia , covering a wide variety of clinical areas. A recent OECD study showed that the focal areas in the West and South of the Netherlands are among the leading clusters in the world for generation biotech patents
  • Our approach is paying off In 2008 a strong growth in attracted venture capital against all odds In the top 10 European biotech-Pharma partnerships, 5 involve Dutch SME’s An example: Prosensa and its partnership with GSK - Development and commercialization of RNA based therapeutics for Duchenne Muscular Dystrophy (DMD) - Deal value of upfront and milestone payments USD 655 million
  • Handen in elkaar slaan Cahier 300x gedownload
  • Handen in elkaar slaan
  • Innovation to commercialization

    1. 1. From innovation to commercialization Willem de Laat Managing Director Life Sciences & Health 8 December 2010
    2. 2. From innovation to commercialization
    3. 3. Global biomedical trends <ul><li>1 Trillion $ sales in 2014 </li></ul><ul><li>150 billion $ patent expirations </li></ul><ul><li>Ongoing consolidation </li></ul><ul><li>75% diseases without cure </li></ul><ul><li>Healthy ageing </li></ul><ul><li>Strong R&D investment </li></ul><ul><li>Ref.: Scrip News, April 2010 </li></ul>
    4. 4. Global R&D spending 1. Roche - $8.7B 2. Pfizer - $7.4B 3. Novartis  - $7.06B 4. Johnson & Johnson  - $6.66B 5. Sanofi-Aventis - $6.25B 6. GlaxoSmithKline -  $5.59B 7. Merck  - $5.58B 8. Takeda Pharmaceuticals - $4.64B 9. AstraZeneca - $4.23B 10. Eli Lilly - $4.13B 11. Bristol-Myers Squibb - $3.48B 12. Boehringer Ingelheim  - $3.03B 13. Abbott Laboratories - $2.61B 14. Daiichi Sankyo - $1.89B 15. Astellas Pharma - $1.63B
    5. 5. H ealth-related life sciences : an important sector in the Dutch economy Drugs Diagnostics Devices Companies Revenues FTE Other Total Source: EIM study for EZ [2006] , Voorstel LSG [2006] Preliminary data Biotech Outlook 2011 430 390 75 935 40 12.0 bn 2.7 bn 0.6 bn 15.7 bn 0.4 bn 37,000 12,000 54,600 3,400 ± 150 companies highly innovative Update 2010: >200 companies highly innovative 3% of GDP 2,200
    6. 6. The Dutch life sciences and health innovation cluster builds upon a strong knowledge base Excellent biobanks and ‘real life’ data infrastructure 120 mile radius Global players & very high concentration of SMEs Excellent universities
    7. 7. 5 of the top 10 European biotech deals are with Dutch companies, with a total value exceeding USD 2 billion
    8. 8. But....the consolidation changing environment has impact on the Netherlands Organon Solvay Crucell
    9. 9. Life Sciences & Health Innovation Program Improving the investment and innovation climate in the Dutch life sciences and health sector Hier komt een screenshot van de homepage 7 dec 5000+ unique visitors/month Database for subsidies and funding Benchmark study on clinical trial performance to map the competitive position of the Netherlands BIO - E UROPE S PRING MARCH 14-16, 2011, MILAN, ITALY Thomson Pharma Bio International Convention, Chicago, 2010
    10. 10. Biotech Outlook 2011 will be launched in Q1 next year <ul><li>Improved cluster assessment method </li></ul><ul><ul><li>Cluster size, output & investments </li></ul></ul><ul><ul><li>Context with major events </li></ul></ul><ul><ul><li>Comparison with international clusters </li></ul></ul><ul><li>Cooperation with international academic institutes </li></ul><ul><li>Cooperation on methodology with Council of European BioRegions </li></ul>Progress
    11. 11. Sector vision 300 downloads
    12. 12. “ TOPGEBIED LIFE SCIENCES” We have to Build, Nurture and Promote it together Health & Wealth
    13. 13. <ul><li>FEN-PHEN CASE (Wyeth) </li></ul><ul><li>Primary Pulmonary Hypertension on anti-obesity drug </li></ul><ul><li>62 deaths before label change (1994) </li></ul><ul><li>First court case (Billiton, Texas) $20 million </li></ul><ul><li>20,000 claims < 1 month </li></ul><ul><li>Discovery / browser /20,000 emails </li></ul><ul><li>Wyeths prior knowledge exposed </li></ul><ul><li>First settlement $1 billion </li></ul><ul><li>Reservations in Liability reserve fund total $21 billion </li></ul><ul><li>Stockprice decreased 50% </li></ul>
    14. 14.
    1. A particular slide catching your eye?

      Clipping is a handy way to collect important slides you want to go back to later.